51.585 USD
-0.53 (-1.03%)
Overall BMRN gets a fundamental rating of 6 out of 10. We evaluated BMRN against 529 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidiy or solvency issues. BMRN is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, BMRN could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
In the past year BMRN had a positive cash flow from operations.
Of the past 5 years BMRN 4 years were profitable.
BMRN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BMRN has a better Return On Assets (6.83%) than 92.44% of its industry peers.
BMRN's Return On Equity of 8.59% is amongst the best of the industry. BMRN outperforms 92.06% of its industry peers.
BMRN has a Return On Invested Capital of 7.69%. This is amongst the best in the industry. BMRN outperforms 93.76% of its industry peers.
BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 18.22%.
The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
BMRN has a Profit Margin of 16.82%. This is amongst the best in the industry. BMRN outperforms 92.63% of its industry peers.
BMRN has a better Operating Margin (20.21%) than 94.52% of its industry peers.
The Gross Margin of BMRN (81.32%) is better than 85.07% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMRN is destroying value.
The number of shares outstanding for BMRN has been increased compared to 1 year ago.
BMRN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BMRN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.05 indicates that BMRN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.05, BMRN is in the better half of the industry, outperforming 73.35% of the companies in the same industry.
BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
BMRN has a Debt to FCF ratio of 0.72. This is amongst the best in the industry. BMRN outperforms 94.33% of its industry peers.
BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BMRN (0.10) is worse than 64.08% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.05 |
ROIC/WACC0.93
WACC8.28%
2.3 Liquidity
BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BMRN (4.83) is comparable to the rest of the industry.
BMRN has a Quick Ratio of 3.10. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN's Quick ratio of 3.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 61.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.00% over the past year.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.39%.
The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
The Earnings Per Share is expected to grow by 27.59% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.34% on average over the next years.
EPS Next Y33.85%
EPS Next 2Y44.64%
EPS Next 3Y33.41%
EPS Next 5Y27.59%
Revenue Next Year12.52%
Revenue Next 2Y10.02%
Revenue Next 3Y9.15%
Revenue Next 5Y7.34%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.39, which indicates a rather expensive current valuation of BMRN.
Based on the Price/Earnings ratio, BMRN is valued cheaply inside the industry as 94.52% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.55. BMRN is valued slightly cheaper when compared to this.
BMRN is valuated reasonably with a Price/Forward Earnings ratio of 11.16.
Based on the Price/Forward Earnings ratio, BMRN is valued cheaply inside the industry as 98.30% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.78, BMRN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.39 | ||
| Fwd PE | 11.16 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaper than 95.46% of the companies in the same industry.
BMRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMRN is cheaper than 97.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12 | ||
| EV/EBITDA | 12.58 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.41% in the coming years.
PEG (NY)0.57
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y33.41%
5. Dividend
5.1 Amount
No dividends for BMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:BMRN (12/16/2025, 10:39:53 AM)
51.585
-0.53 (-1.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.86%
Inst Owner Change-1%
Ins Owners0.65%
Ins Owner Change-0.62%
Market Cap9.91B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts82.35
Price Target92.97 (80.23%)
Short Float %4.32%
Short Ratio2.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-2.86%
PT rev (3m)-5.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.04%
EPS NY rev (1m)-2.6%
EPS NY rev (3m)-15.23%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)1.24%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.39 | ||
| Fwd PE | 11.16 | ||
| P/S | 3.2 | ||
| P/FCF | 12 | ||
| P/OCF | 10.84 | ||
| P/B | 1.64 | ||
| P/tB | 1.76 | ||
| EV/EBITDA | 12.58 |
EPS(TTM)2.66
EY5.16%
EPS(NY)4.62
Fwd EY8.96%
FCF(TTM)4.3
FCFY8.33%
OCF(TTM)4.76
OCFY9.22%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.57
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.05 |
F-Score8
WACC8.28%
ROIC/WACC0.93
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y33.85%
EPS Next 2Y44.64%
EPS Next 3Y33.41%
EPS Next 5Y27.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.52%
Revenue Next 2Y10.02%
Revenue Next 3Y9.15%
Revenue Next 5Y7.34%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.31%
EBIT Next 3Y38.69%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
Can you provide the valuation status for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 33.85% in the next year.